Carbapenemase-producing Klebsiella pneumoniae

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Robilotti, Elizabeth ^a   Deresinski, Stan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; AZTREONAM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DORIPENEM; ERAVACYCLINE; FOSFOMYCIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; PLAZOMICIN; RIFAMPICIN; TIGECYCLINE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENETICS; BACTERIUM IDENTIFICATION; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; GENETIC CODE; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PUBLIC HEALTH;

KLEBSIELLA PNEUMONIAE;

EID: 84907049122     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-80     Document Type: Article

References (68)

1. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Group NCSP, Henderson DK, Palmore TN, Segre JA: Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012, 4:148ra116.
2. Centers for Disease Control and Prevention: Antibiotic Resistance Threats in the United States, 2013. U.S Department of Health and Human Sciences; 2013. [http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf]
3. Centers for DiseaseC, Prevention: Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013, 62:165-70.
4. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC: Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001, 45:1151-61.
5. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC: Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2008, 52:809.
6. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL: Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.
7. Chen LF, Anderson DJ, Paterson DL: Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance. Infect Drug Resist 2012, 5:133-41.
8. Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, Kassis I: Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 2013, 83:307-13.
9. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y: Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-33.
10. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP: Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-106.
11. Centers for Disease Control and Prevention: 2012 CRE Toolkit - Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). U.S Department of Health and Human Sciences; 2012. [http://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf]
12. Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, Patel JB: Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010, 54:4201-7.
13. CDC: Multiplex Real-Time PCR Detection of Klebsiella pneunoniae Carbapenemase (KPC) and New Delhi metallo-β-lactamase (NDM-1) genes. U.S Department of Health and Human Sciences; 2011. [http://www.cdc.gov/HAI/settings/lab/kpc-ndm1-labprotocol.html]
14. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement (January 2014). 2014. [http://shopping.netsuite.com/c.1253739/site/Sample-pdf/M100S24-sample.pdf]
15. Gazin M, Paasch F, Goossens H, Malhotra-Kumar S, Mosar WP, Teams SWS: Current trends in culture-based and molecular detection of extended-spectrum-beta-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2012, 50:1140-6.
16. Nordmann P, Poirel L,Dortet L: Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2012, 18:1503-7.
17. Yan Y, Sun K, Pan L, Fan H, Yang H, Lu Y, Shi Y: A screening strategy for phenotypic detection of carbapenemase in the clinical laboratory. Can J Microbiol 2014, 60:211-5.
18. Tsakris A, Kristo I, Poulou A, Themeli-Digalaki K, Ikonomidis A, Petropoulou D, Pournaras S, Sofianou D: Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J Clin Microbiol 2009, 47:362-7.
19. Bernabeu S, Poirel L, Nordmann P: Spectrophotometry-based detection of carbapenemase producers among Enterobacteriaceae. Diagn Microbiol Infect Dis 2012, 74:88-90.
20. Burckhardt I, Zimmermann S: Using matrix-assisted laser desorption ionization-time of flight mass spectrometry to detect carbapenem resistance within 1 to 2.5 hours. J Clin Microbiol 2011, 49:3321-4.
21. Altun O, Almuhayawi M, Ullberg M, Ozenci V: Clinical evaluation of the FilmArray blood culture identification panel in identification of bacteria and yeasts from positive blood culture bottles. J Clin Microbiol 2013, 51:4130-6.
22. Sullivan KV, Deburger B, Roundtree SS, Ventrola CA, Blecker-Shelly DL, Mortensen JE: Rapid Detection of Inpatient Gram-Negative Bacteremia; Extended-Spectrum Beta-Lactamases and Carbapenemase Resistance Determinants with the Verigene BC-GN Test: A Multi-Center Evaluation. J Clin Microbiol 2014, 52:2416-21.
23. Tenover FC, Canton R, Kop J, Chan R, Ryan J, Weir F, Ruiz-Garbajosa P, LaBombardi V, Persing DH: Detection of colonization by carbapenemase-producing Gram-negative Bacilli in patients by use of the Xpert MDRO assay. J Clin Microbiol 2013, 51:3780-7.
24. Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM: Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004, 48:4793-9.
25. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, Karumudi U, Tolaney P, Quale J: Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005, 49:3018-20.
26. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, et al.: Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013, 13:785-96.
27. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG: Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009, 53:3365-70.
28. Centers for Disease C, Prevention: Notes from the Field: New Delhi Metallo-β-Lactamase-Producing Escherichia coli Associated with Endoscopic Retrograde Cholangiopancreatography - Illinois, 2013. MMWR Morb Mortal Wkly Rep 2014, 62:1051.
29. Healthcare-associated Infections (HAIs): Tracking CRE. [http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html]
30. Guh AY, Limbago BM, Kallen AJ: Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Rev Anti Infect Ther 2014, 12:565-80.
31. Mathers AJ, Cox HL, Kitchel B, Bonatti H, Brassinga AK, Carroll J, Scheld WM, Hazen KC, Sifri CD: Molecular dissection of an outbreak of carbapenem-resistant enterobacteriaceae reveals Intergenus KPC carbapenemase transmission through a promiscuous plasmid. MBio 2011, 2:e00204-11.
32. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P: Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. Antimicrob Agents Chemother 2008, 52:1257-63.
33. Wang Y, Cao W, Zhu X, Chen Z, Li L, Zhang B, Wang B, Tian L, Wang F, Liu C, et al.: Characterization of a novel Klebsiella pneumoniae sequence type 476 carrying both bla KPC-2 and bla IMP-4. Eur J Clin Microbiol Infect Dis 2012, 31:1867-72.
34. Munoz-Price LS, Quinn JP: Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2013, 26:378-87.
35. Kruse EB, Aurbach U, Wisplinghoff H: Carbapenem-Resistant Enterobacteriaceae: Laboratory Detection and Infection Control Practices. Curr Infect Dis Rep 2013, [Epub ahead of print].
36. Palmore TN, Henderson DK: Carbapenem-resistant enterobacteriaceae: a call for cultural change. Ann Intern Med 2014, 160:567-9.
37. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y; Israel Carbapenem-Resistant Enterobacteriaceae Working G: Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011, 52:848-55.
38. Deresinski SC, Schirmer P: Management of infections due to KPC-producing Klebsiella pneumoniae. F1000 Med Rep 2009, 1:79.
39. Petrosillo N, Giannella M, Lewis R, Viale P: Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013, 11:159-77.
40. Lee GC, Burgess DS: Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 2012, 11: 32.
41. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, MarkogiannakisA,GoukosD, SkoutelisA: Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems. Antimicrob Agents Chemother 2014, 58:2322-8.
42. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M: Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55:943-50.
43. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, Jacobs MR, Bonomo RA: In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010, 54:526-9.
44. Kaase M, Szabados F, Anders A, Gatermann S: Fosfomycin Susceptibility in Carbapenem-Resistant Enterobacteriaceae from Germany. J Clin Microbiol 2014, 52:1893-7.
45. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, Spyridopoulou K, Daikos GL: Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012, 67:2777-9.
46. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H: Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014, 43:52-9.
47. Tangden T, Hickman RA, Forsberg P, Lagerback P, Giske CG, Cars O: Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments. Antimicrob Agents Chemother 2014, 58:1757-62.
48. Urban C, Mariano N, Rahal JJ: In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010, 54:2732-4.
49. Elemam A, Rahimian J, Doymaz M: In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010, 48:3558-62.
50. Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F: Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:3990-3.
51. Pankey GA, Ashcraft DS: Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011, 70:561-4.
52. Giamarellou H, Galani L, Baziaka F, Karaiskos I: Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:2388-90.
53. Oliva A, D 'Abramo A, D'Agostino C, Iannetta M, Mascellino MT, Gallinelli C, Mastroianni CM, Vullo V: Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother 2014, 69:1718-20.
54. Lamoureaux TL, Frase H, Antunes NT, Vakulenko SB: Antibiotic resistance and substrate profiles of the class A carbapenemase KPC-6. Antimicrob Agents Chemother 2012, 56:6006-8.
55. thAnnual Meeting of the Infectious Diseases Society of America: 20-23 October 2011; Boston, MA.
56. Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, Inkaya AC, De Pascale G, Grilli E, Tumbarello M, et al.: Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother 2014, 58:851-8.
57. Gordon NC, Png K, Wareham DW: Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:5316-22.
58. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, Shanks RM, Doi Y: Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 2013, 57:2103-8.
59. Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A, Espejo-Gutierrez de Tena E, Artero-Gonzalez ML, Corcia-Palomo Y, Bautista-Paloma J: Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 2013, 59:225-31.
60. Drawz SM, Papp-Wallace KM, Bonomo RA: New beta-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World. Antimicrob Agents Chemother 2014, 58:1835-46.
61. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, et al.: Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem 2013, 288:27960-71.
62. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN: Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012. Antimicrob Agents Chemother 2014, 58:1684-92.
63. Mushtaq S, Woodford N, Hope R, Adkin R, Livermore DM: Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother 2013, 68:1601-8.
64. Page MG, Dantier C, Desarbre E: In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother 2010, 54:2291-302.
65. Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, Walpole SM, Horn PT: Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 2014, 58:1847-54.
66. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH: Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013, 57:5548-58.
67. Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Redican, S, Nicolau DP: Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 2014, 58:2113-8.
68. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N: Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011, 66:48-53.